Oxford Immune Algorithmics Announces Appointment Of Pioneering Academic Dr. Jason Berman To Its Scientific Advisory Board

Oxford Immune Algorithmics’ trajectory as a Medtech and Biotech company continues to accelerate. The award-winning company recently announced the appointment of pioneering and internationally recognised academic Dr. Jason Berman to its Advisory Scientific Board. 

Dr. Berman is a widely respected clinician, researcher and thought leader, and serves as CEO and Scientific Director of the Children’s Hospital of Eastern Ontario (CHEO) Research Institute and as Vice President for Research, at CHEO. He is also a Full Professor of Paediatrics and Cellular and Molecular Medicine at the University of Ottawa, having previously served as Professor of Pediatrics, Microbiology, Immunology and Pathology at Dalhousie University , and as interim Vice President for Research, Innovation and Knowledge Translation at the IWK Health Centre in Halifax, Nova Scotia.

Dr Berman is also well known for his systems-thinking approach and pioneering research, as evidenced in his zebrafish modelling of childhood cancer and orphan diseases. He is past President of the Canadian Society of Clinical Investigation, President of the Canadian Haematology Society, and a founding member of the Canadian Rare Disease Models and Mechanisms Network.

Oxford Immune Algorithmics announced the appointment of Dr. Jason Berman on the heels of the start-up’s graduation from the Canadian Creative Destruction Lab (CDL), having secured funding and a place among the top 3 participants in its most recent mentorship round. 

Oxford Immune Algorithmics recently announced the appointment of Dr. Jason Berman on the heels of the start-up’s graduation from Canadian Creative Destruction Lab (CDL) after it secured a top 3 place from its most recent mentorship round program and successful funding.

Oxford Immune Algorithmics (OIA) is an award-winning Bio and MedTech company incubated by the University of Oxford with a mission to rid the world of preventable diseases. It operates multi-nationally to build technology that moves healthcare away from its reliance on population-wide symptom pattern matching toward value-based precision medicine and personalised diagnostics.